Eczema, clinically termed atopic dermatitis (AD), is a prevalent, chronic inflammatory skin condition characterized by relapsing pruritic lesions. Often described as “the itch that rashes,” AD significantly impacts patients’ quality of life due to persistent discomfort and susceptibility to secondary infections. This article delves into the complexities of atopic eczema, with a particular focus on its differential diagnosis. Understanding the nuances of AD and its mimics is crucial for accurate diagnosis and effective patient management. We will explore the diverse conditions that can present similarly to atopic eczema, emphasizing the importance of a thorough clinical evaluation and strategic diagnostic approaches. This discussion aims to equip healthcare professionals with the knowledge to confidently differentiate atopic eczema from other dermatological conditions, ensuring optimal patient outcomes through targeted treatment strategies and minimizing the adverse effects of misdiagnosis and poorly managed eczema.
Introduction
Atopic dermatitis (AD), the most common type of eczema, affects a significant portion of the global population, particularly children. Its multifactorial etiology, involving genetic predisposition, environmental triggers, and immune dysregulation, contributes to the diagnostic challenges it presents. While the hallmark symptoms of dry, itchy skin and characteristic rash distribution often point towards AD, numerous other dermatological conditions can mimic its presentation. Accurate diagnosis is paramount as inappropriate treatment can exacerbate the patient’s condition and delay effective management. This article provides an in-depth exploration of the differential diagnosis of atopic eczema, highlighting key distinguishing features and diagnostic considerations to aid clinicians in effectively differentiating AD from its clinical mimics.
Etiology of Atopic Eczema
The precise cause of atopic eczema remains elusive, but it is widely accepted that AD arises from a complex interplay of genetic and environmental factors.
Genetic Predisposition
Genetics play a substantial role in susceptibility to AD. Individuals with a family history of atopy, including eczema, asthma, and allergic rhinitis, are at a heightened risk. Several genes have been identified as contributing to AD pathogenesis, primarily those involved in skin barrier integrity and immune system function.
Filaggrin Gene (FLG)
The filaggrin gene (FLG) is among the most extensively studied genes in AD. Filaggrin is a crucial protein for maintaining the skin’s barrier function. Mutations in FLG impair the skin barrier, increasing permeability to irritants and allergens and leading to transepidermal water loss. This genetic defect is a significant predisposing factor for developing eczema.
Other Skin Barrier Genes
Beyond FLG, other genes critical for skin barrier function are implicated in AD. These include genes involved in ceramide synthesis and transport, such as ceramide synthase genes and ABCA12. These genes ensure the structural integrity and lipid composition of the stratum corneum, the outermost layer of the skin.
Immune-Related Genes
Immune dysregulation is a central feature of AD. Several immune-related genes have been linked to AD, including those regulating T-cells, cytokines, and immunoglobulin responses. Key genes in this category include interleukin genes (IL-4, IL-13, IL-31), signal transducer and activator of transcription (STAT3), and Fc fragment of IgE receptor Ig (FCER1G). These genes contribute to the type 2 helper T cell (Th2) immune response, which is characteristically overactive in AD, driving inflammation and pruritus.
Genetic factors in eczema are multifaceted and polygenic. While genetic testing is not a routine diagnostic tool for AD, understanding the genetic underpinnings helps in risk assessment and personalized management strategies.
Environmental Triggers
Environmental factors significantly influence the onset and exacerbation of eczema. Patients with AD have a compromised skin barrier, making them more vulnerable to environmental irritants and allergens. Common triggers for eczema flares include:
- Irritants: Detergents, soaps, solvents, fragrances, and certain skincare products.
- Allergens: Dust mites, pet dander, pollens, molds, and specific foods (especially in children).
- Climate: Changes in temperature and humidity, both extremes of hot and cold, and dry air.
- Stress: Psychological stress can exacerbate eczema symptoms.
- Infections: Bacterial, viral, or fungal infections can trigger or worsen eczema flares.
Immune System Activation in Eczema
The immune system plays a pivotal role in AD pathogenesis. In individuals with AD, the immune system exhibits an exaggerated response to environmental triggers, leading to chronic inflammation and skin damage. This involves a complex interplay of immune cells and cytokines, particularly the Th2 pathway, which releases cytokines like IL-4, IL-13, and IL-31, contributing to itch, inflammation, and barrier dysfunction.
Epidemiology of Atopic Eczema
Atopic eczema is a widespread condition, with lifetime prevalence rates estimated at 15% to 30% in children and 2% to 10% in adults. A significant majority of cases, approximately 60%, manifest within the first year of life. Interestingly, the prevalence tends to be higher in rural compared to urban settings, suggesting a complex interaction with environmental and lifestyle factors.
AD is a key component of the “atopic march,” the progression from atopic dermatitis to other allergic conditions like asthma and allergic rhinitis. Approximately 50% of individuals with severe eczema will develop asthma, and about 75% will experience allergic rhinitis. This highlights the systemic nature of atopy and the importance of early recognition and management of eczema to potentially modify the course of allergic diseases.
Pathophysiology of Atopic Eczema
The pathophysiology of atopic eczema is characterized by skin barrier dysfunction and immune dysregulation. Genetic mutations, particularly in FLG, lead to a compromised stratum corneum with disorganized corneocytes. This structural defect results in a “leaky” skin barrier, causing increased transepidermal water loss and reduced protection against external irritants and allergens.
Furthermore, patients with AD exhibit reduced levels of β-defensins, antimicrobial peptides crucial for defense against pathogens. This deficiency increases susceptibility to microbial colonization and infections, notably with Staphylococcus aureus (S. aureus). S. aureus colonization can exacerbate inflammation and complicate eczema management.
Histopathology of Atopic Eczema
Histopathological findings in eczema are not specific but can support the clinical diagnosis and help differentiate it from other conditions in ambiguous cases. In acute eczematous lesions, characterized by intensely pruritic, erythematous papules, histology reveals:
- Mild epidermal hyperplasia: Thickening of the epidermis.
- Lymphocytic and macrophage infiltration: Immune cell infiltration around dermal blood vessels.
- Spongiosis: Intercellular edema within the epidermis, a hallmark of acute eczema.
Chronic eczema lesions, marked by lichenification and fibrotic papules, show:
- Increased epidermal hyperplasia and hyperkeratosis: More pronounced thickening and scaling of the skin.
- Persistent dermal inflammatory infiltrate: Ongoing immune cell presence in the dermis.
- Reduced or absent spongiosis: Less epidermal edema compared to acute lesions.
While histopathology is not routinely required for diagnosing typical eczema, it can be valuable in ruling out other conditions, particularly in cases where clinical presentation is atypical or unresponsive to standard treatment.
History and Physical Examination in Diagnosing Atopic Eczema
Diagnosis of atopic eczema is primarily clinical, relying on a detailed patient history and thorough physical examination.
History
Key historical features suggestive of atopic eczema include:
- Pruritus: Intense itching is the cardinal symptom.
- Recurrent rash: Chronic or relapsing course of skin eruptions.
- Personal or family history of atopy: Eczema, asthma, allergic rhinitis.
- Onset in childhood: Although it can occur at any age, onset is common in infancy and childhood.
- Triggers: Identification of factors that exacerbate symptoms (irritants, allergens, stress, etc.).
Physical Examination
Physical examination findings in eczema vary with the phase and age of the patient.
Acute Eczema
- Erythematous papules and plaques: Red, raised lesions.
- Excoriations: Scratch marks due to pruritus.
- Vesicles and weeping: Small blisters and oozing may be present in acute flares.
Chronic Eczema
- Lichenification: Thickened, leathery skin with exaggerated skin markings from chronic scratching.
- Dryness and scaling: Persistent dry, flaky skin.
- Fissures: Cracks in the skin, especially in areas of lichenification.
Distribution Patterns by Age
- Infants: Widespread distribution, often involving the face (cheeks), scalp, and extensor surfaces.
- Children: More localized, typically affecting flexural surfaces (wrists, elbows, ankles, knees), neck, and eyelids.
- Adults: Flexural involvement is common, but hand and foot eczema, and generalized forms are also seen.
Associated Physical Findings
- Dennie-Morgan lines: Creases beneath the lower eyelids, present in up to 25% of AD patients.
- Pityriasis alba: Hypopigmented patches with fine scaling, often on the face.
- Hyperlinear palms: Increased number and depth of skin lines on the palms.
- Allergic salute: Transverse nasal crease from repeated upward rubbing of the nose in allergic rhinitis.
Evaluation and Diagnostic Approach for Atopic Eczema
Diagnosis of atopic eczema is primarily clinical, based on established criteria such as the Hanifin and Rajka criteria or the UK diagnostic criteria. Routine laboratory tests are not typically required. However, in certain situations, additional investigations may be considered to confirm the diagnosis or rule out differential diagnoses.
Diagnostic Criteria
Clinical criteria for AD emphasize the presence of essential features (pruritus, eczema, chronic or relapsing course) and major and minor features. These criteria aid in standardizing diagnosis and are particularly useful in research and clinical trials.
Allergy Testing
Allergy testing (skin prick tests or serum specific IgE) may be considered in patients with:
- Suspected allergic triggers: To identify specific allergens that may be exacerbating eczema.
- Food allergies: Particularly in young children with eczema unresponsive to standard treatment.
- Environmental allergies: To guide allergen avoidance strategies.
However, it’s crucial to interpret allergy test results cautiously, as sensitization does not always equate to clinical relevance.
Patch Testing
Patch testing is indicated when contact dermatitis is suspected as a differential diagnosis or a contributing factor to eczema flares. Patch testing helps identify specific contact allergens that may be causing or worsening the skin condition.
Skin Biopsy
Skin biopsy is rarely needed for typical eczema but may be considered in cases with:
- Atypical presentation: To rule out other dermatological conditions.
- Unresponsiveness to treatment: To exclude conditions mimicking eczema.
- Suspected infection: To identify or rule out secondary skin infections.
Differential Diagnosis of Atopic Eczema
The differential diagnosis of atopic eczema is broad and includes various eczematous and non-eczematous dermatoses. Accurate differentiation is crucial for appropriate management. Key conditions to consider include:
1. Contact Dermatitis
Contact dermatitis, either irritant or allergic, is a common mimic of atopic eczema.
- Irritant Contact Dermatitis: Caused by direct skin damage from irritants (soaps, detergents, chemicals). Typically presents with burning, stinging, and erythema, often in areas of direct contact. History of exposure to irritants is crucial.
- Allergic Contact Dermatitis: A delayed hypersensitivity reaction to allergens (poison ivy, nickel, fragrances). Characterized by pruritus, erythema, vesicles, and papules in a distribution pattern suggestive of allergen exposure. Patch testing is essential for diagnosis.
Distinguishing from Atopic Eczema: Contact dermatitis often has a more acute onset related to specific exposures, whereas atopic eczema is typically chronic and relapsing with a personal or family history of atopy. Distribution and history of exposure are key differentiators.
2. Seborrheic Dermatitis
Seborrheic dermatitis is a common inflammatory condition affecting sebum-rich areas like the scalp, face, and chest.
- Presentation: Characterized by erythematous patches with greasy scales. Common in infants (“cradle cap”) and adults.
- Distribution: Scalp, eyebrows, nasolabial folds, chest.
Distinguishing from Atopic Eczema: Seborrheic dermatitis typically has greasy, yellowish scales compared to the drier scales of atopic eczema. Distribution in sebum-rich areas and lack of intense pruritus (compared to AD) are distinguishing features.
3. Psoriasis
Psoriasis is a chronic autoimmune condition characterized by raised, scaly plaques.
- Presentation: Well-defined, erythematous plaques with silvery scales.
- Distribution: Extensor surfaces (elbows, knees), scalp, nails.
Distinguishing from Atopic Eczema: Psoriasis plaques are typically thicker, well-demarcated, and have silvery scales, unlike the less defined, often weeping lesions of acute eczema. Nail involvement (pitting, onycholysis) and Auspitz sign (punctate bleeding upon scale removal) are suggestive of psoriasis.
4. Cutaneous Fungal Infections (Tinea)
Tinea infections, caused by dermatophyte fungi, can mimic eczema, particularly tinea corporis (ringworm).
- Presentation: Annular (ring-shaped) lesions with central clearing and scaly, raised borders. Pruritic.
Distinguishing from Atopic Eczema: Tinea lesions are typically more circular with a raised, scaly border and central clearing, unlike the more diffuse and less defined patches of eczema. Potassium hydroxide (KOH) examination of skin scrapings confirms fungal infection.
5. Scabies
Scabies is a contagious infestation caused by the Sarcoptes scabiei mite.
- Presentation: Intense pruritus, especially at night, with small papules, vesicles, and burrows (thin, wavy lines) most commonly found in interdigital spaces, wrists, and genitals.
Distinguishing from Atopic Eczema: Scabies is intensely itchy, especially at night, and often affects multiple family members due to its contagious nature. Burrows, if present, are pathognomonic. Skin scraping and microscopic examination reveal mites, eggs, or fecal pellets.
6. Nummular Eczema (Discoid Eczema)
Nummular eczema presents with coin-shaped (nummular) plaques of eczema.
- Presentation: Circular, well-demarcated plaques of eczema, often intensely pruritic.
Distinguishing from Atopic Eczema: Nummular eczema features distinct, coin-shaped plaques, while atopic eczema tends to be more diffusely distributed and less well-defined in plaque morphology. However, nummular eczema is sometimes considered a variant of atopic eczema.
7. Dyshidrotic Eczema (Pompholyx)
Dyshidrotic eczema is characterized by vesicles on the hands and feet.
- Presentation: Sudden onset of small, intensely pruritic vesicles on the palms, soles, and sides of fingers and toes.
Distinguishing from Atopic Eczema: Dyshidrotic eczema is characterized by vesicular eruptions primarily on hands and feet, unlike the more varied distribution and lesion morphology of atopic eczema.
8. Drug Eruptions
Certain medications can cause eczematous drug eruptions.
- Presentation: Can mimic various eczematous patterns. Onset often temporally related to starting a new medication.
Distinguishing from Atopic Eczema: Temporal association with medication initiation is a key clue. Drug eruptions often resolve upon discontinuation of the offending drug. Careful medication history is essential.
9. Ectodermal Dysplasia
Ectodermal dysplasias are a group of genetic disorders affecting ectoderm-derived structures, including skin, hair, teeth, and nails. Some types can present with eczema-like skin findings.
- Presentation: Eczema-like rash associated with abnormalities in hair, teeth, and nails.
Distinguishing from Atopic Eczema: Presence of other ectodermal abnormalities (hair, teeth, nail changes) distinguishes ectodermal dysplasia. Genetic testing may be required for definitive diagnosis.
10. Hyper-IgE Syndrome (Job Syndrome)
Hyper-IgE syndrome is a rare primary immunodeficiency characterized by elevated IgE levels, recurrent infections, and eczema-like dermatitis.
- Presentation: Severe eczema, recurrent S. aureus skin abscesses, pneumonia, and markedly elevated IgE levels.
Distinguishing from Atopic Eczema: Severe, treatment-resistant eczema with recurrent infections and high IgE levels are suggestive of Hyper-IgE syndrome. Immunological evaluation is necessary.
11. Netherton Syndrome
Netherton syndrome is a rare genetic disorder characterized by ichthyosis, hair shaft abnormalities (bamboo hair), and atopic dermatitis-like skin inflammation.
- Presentation: Ichthyosis linearis circumflexa (characteristic skin scaling), bamboo hair, and eczema.
Distinguishing from Atopic Eczema: Ichthyosis and bamboo hair are hallmark features of Netherton syndrome, differentiating it from typical atopic eczema. Genetic testing confirms the diagnosis.
12. Wiskott-Aldrich Syndrome
Wiskott-Aldrich syndrome is an X-linked primary immunodeficiency characterized by eczema, thrombocytopenia, and recurrent infections.
- Presentation: Eczema, petechiae and bleeding (due to thrombocytopenia), recurrent infections.
Distinguishing from Atopic Eczema: Thrombocytopenia and recurrent infections in addition to eczema suggest Wiskott-Aldrich syndrome. Platelet count and immunological evaluation are crucial.
Treatment and Management of Atopic Eczema
The primary goals in managing atopic eczema are to reduce symptoms, control flares, prevent infections, and improve quality of life. Management strategies include:
Basic Skin Care
- Emollients: Regular use of fragrance-free ointments and creams to hydrate and restore skin barrier function. Ointments are generally preferred over lotions due to higher oil content.
- Gentle Cleansing: Avoiding harsh soaps and cleansers; using mild, fragrance-free cleansers.
- Trigger Avoidance: Identifying and minimizing exposure to irritants and allergens.
Topical Anti-inflammatory Medications
- Topical Corticosteroids (TCS): First-line treatment for flares. Potency should be appropriate for the body area and severity. Intermittent use for active lesions and proactive therapy (twice weekly application to previously affected areas) can prevent flares.
- Topical Calcineurin Inhibitors (TCIs): Pimecrolimus and tacrolimus are steroid-sparing agents for mild to moderate eczema, particularly useful for facial and intertriginous areas where TCS side effects are more concerning.
- Crisaborole Ointment (Eucrisa): A non-steroidal phosphodiesterase-4 inhibitor, effective for mild to moderate eczema.
Systemic Therapies
Systemic treatments are reserved for severe, refractory eczema.
- Systemic Corticosteroids: Oral corticosteroids for short-term management of severe flares. Not for long-term use due to side effects.
- Immunosuppressants: Cyclosporine, methotrexate, azathioprine, mycophenolate mofetil are used in severe cases.
- Biologics: Dupilumab (anti-IL-4Rα) is approved for moderate to severe AD, targeting the Th2 pathway. Other biologics are under investigation.
- Janus Kinase (JAK) Inhibitors: Oral and topical JAK inhibitors are emerging therapies for AD.
Management of Pruritus
- Topical treatments: Emollients, TCS, TCIs help reduce itch by controlling inflammation and dryness.
- Oral Antihistamines: Sedating antihistamines (hydroxyzine, diphenhydramine) may be helpful for nighttime pruritus to improve sleep, but non-sedating antihistamines are generally not effective for eczema-related itch.
Infection Management
- Topical Antibiotics: Mupirocin or fusidic acid for localized bacterial infections.
- Systemic Antibiotics: For more extensive bacterial infections or cellulitis.
- Antiviral Medications: Acyclovir or valacyclovir for eczema herpeticum.
- Diluted Bleach Baths: May reduce S. aureus colonization and infection rates in recurrently infected eczema.
- Intranasal Mupirocin: To reduce nasal S. aureus carriage.
Toxicity and Adverse Effect Management of Eczema Treatments
Patients and caregivers must be educated about potential side effects of eczema treatments.
Topical Corticosteroids
- Local Side Effects: Skin atrophy, striae, telangiectasias, acne, folliculitis, hypopigmentation. Risk is higher with potent steroids and prolonged use. Use lower potency steroids on the face and intertriginous areas.
- Systemic Absorption: Minimal with appropriate use, but possible with high potency steroids, large surface area application, and occlusive dressings.
Topical Calcineurin Inhibitors
- Transient Burning and Itching: Common initially upon application.
- Black Box Warning (rare malignancy risk): Long-term risk is considered low, but use should be balanced with benefits.
Systemic Therapies
Systemic corticosteroids and immunosuppressants have various potential side effects requiring careful monitoring. Biologics and JAK inhibitors also have specific adverse effect profiles.
Prognosis of Atopic Eczema
The prognosis for atopic eczema varies. Many children experience improvement or resolution of symptoms by adulthood. However, persistence into adulthood is more likely in individuals with severe childhood eczema, later onset, or persistent disease. Even in those who “outgrow” childhood eczema, there may be an increased risk of hand eczema and other atopic conditions in adulthood.
Complications of Atopic Eczema
Complications of eczema primarily relate to skin barrier dysfunction and chronic inflammation.
Skin Infections
- Bacterial Infections: S. aureus is the most common bacterial pathogen, leading to impetigo, cellulitis, furuncles.
- Viral Infections: Eczema herpeticum (HSV-1 infection) is a serious complication requiring urgent treatment. Eczema coxsackium (Coxsackievirus A16) is another viral infection that can present atypically in eczema patients.
- Fungal Infections: Malassezia and dermatophytes can cause secondary infections.
Eczema Herpeticum
Eczema herpeticum is a dermatologic emergency characterized by rapid onset of painful vesicles and erosions, fever, and systemic symptoms. Prompt antiviral treatment is crucial to prevent serious complications.
Psychological Impact
Chronic eczema can significantly affect quality of life, leading to sleep disturbance, emotional distress, anxiety, and depression.
Deterrence and Patient Education for Atopic Eczema
Patient education is paramount in eczema management. Key aspects include:
- Understanding Triggers: Identifying and avoiding personal triggers.
- Skin Care Regimen: Emphasizing daily emollient use, gentle cleansing, and appropriate use of topical medications.
- Flare Management: Recognizing early signs of flares and initiating treatment promptly.
- Infection Prevention: Maintaining good hygiene and recognizing signs of skin infection.
- Realistic Expectations: Eczema is a chronic condition with flares and remissions; management is ongoing.
Enhancing Healthcare Team Outcomes in Atopic Eczema Management
Optimal care for patients with atopic eczema requires a collaborative interprofessional approach. Primary care providers often manage mild to moderate eczema. Dermatologists are essential for moderate to severe cases, complex management, and differential diagnosis challenges. Allergists may be consulted for allergy evaluation and management of allergic triggers. Nurses, especially dermatology-trained nurses, play a crucial role in patient education, treatment adherence, and follow-up. Pharmacists ensure appropriate medication use and counsel patients on topical therapy. This team-based approach ensures comprehensive care and improved outcomes for individuals with atopic eczema.
Conclusion
Atopic eczema presents a significant diagnostic challenge due to its varied clinical presentations and overlap with numerous other dermatological conditions. A thorough understanding of the differential diagnosis of atopic eczema is critical for accurate diagnosis and effective management. By carefully considering the patient’s history, physical examination findings, and, when necessary, utilizing diagnostic tools like allergy testing, patch testing, and skin biopsy, clinicians can confidently differentiate atopic eczema from its mimics. This precise diagnostic approach ensures that patients receive targeted and effective treatment, optimizing outcomes and improving their quality of life while minimizing the risks associated with misdiagnosis and inappropriate management. Continued education and collaborative interprofessional care are essential to enhance the management of this prevalent and often challenging skin condition.
References
1.Kantor R, Thyssen JP, Paller AS, Silverberg JI. Atopic dermatitis, atopic eczema, or eczema? A systematic review, meta-analysis, and recommendation for uniform use of ‘atopic dermatitis’. Allergy. 2016 Oct;71(10):1480-5. [PMC free article: PMC5228598] [PubMed: 27392131]
2.Brown SJ. Molecular mechanisms in atopic eczema: insights gained from genetic studies. J Pathol. 2017 Jan;241(2):140-145. [PubMed: 27659773]
3.Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020 Jan;124(1):36-43. [PubMed: 31622670]
4.Rice NE, Patel BD, Lang IA, Kumari M, Frayling TM, Murray A, Melzer D. Filaggrin gene mutations are associated with asthma and eczema in later life. J Allergy Clin Immunol. 2008 Oct;122(4):834-836. [PMC free article: PMC2775129] [PubMed: 18760831]
5.Jungersted JM, Agner T. Eczema and ceramides: an update. Contact Dermatitis. 2013 Aug;69(2):65-71. [PubMed: 23869725]
6.Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, Berger TG, Bergman JN, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51. [PMC free article: PMC4410183] [PubMed: 24290431]
7.Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019 Mar;180(3):464-474. [PubMed: 29969827]
8.Clausen ML, Edslev SM, Andersen PS, Clemmensen K, Krogfelt KA, Agner T. Staphylococcus aureus colonization in atopic eczema and its association with filaggrin gene mutations. Br J Dermatol. 2017 Nov;177(5):1394-1400. [PubMed: 28317091]
9.White CR. Histopathology of exogenous and systemic contact eczema. Semin Dermatol. 1990 Sep;9(3):226-9. [PubMed: 2206924]
10.Dutta A, De A, Das S, Banerjee S, Kar C, Dhar S. A Cross-Sectional Evaluation of the Usefulness of the Minor Features of Hanifin and Rajka Diagnostic Criteria for the Diagnosis of Atopic Dermatitis in the Pediatric Population. Indian J Dermatol. 2021 Nov-Dec;66(6):583-590. [PMC free article: PMC8906322] [PubMed: 35283501]
11.Mevorah B, Frenk E, Wietlisbach V, Carrel CF. Minor clinical features of atopic dermatitis. Evaluation of their diagnostic significance. Dermatologica. 1988;177(6):360-4. [PubMed: 3234581]
12.Kamińska E. [The role of emollients in atopic dermatitis in children]. Dev Period Med. 2018;22(4):396-403. [PMC free article: PMC8522819] [PubMed: 30636240]
13.Siegfried EC, Hebert AA. Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications. J Clin Med. 2015 May 06;4(5):884-917. [PMC free article: PMC4470205] [PubMed: 26239454]
14.Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): A systematic review and meta-analysis. J Am Acad Dermatol. 2016 Oct;75(4):681-687.e11. [PMC free article: PMC5216177] [PubMed: 27544489]
15.Ong PY, Leung DY. Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review. Clin Rev Allergy Immunol. 2016 Dec;51(3):329-337. [PubMed: 27377298]
16.Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am. 2010 Aug;30(3):309-21. [PMC free article: PMC2913147] [PubMed: 20670815]
17.Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, Yi D, Zhao B. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006 Oct;155(4):680-7. [PubMed: 16965415]
18.Wetzel S, Wollenberg A. [Eczema herpeticatum]. Hautarzt. 2004 Jul;55(7):646-52. [PubMed: 15150652]
19.Nemeth V, Syed HA, Evans J. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 1, 2024. Eczema. [PubMed: 30855797]
